Anders Nordström, Chairman
Mr. Nordström has a long and versatile professional experience from executive positions in Life Science companies such as CFO, Executive Vice President and as a Board Member in global life science companies and Startup companies e.g. Halo Genomics. He has held executive positions in Phadia, Pharmacia as well as in ArthroCare International including international assignments in the US and Canada. He is currently working as Senior Advisor, Business Development at Uppsala Innovation Centre and has served as Chairman of the Board in several companies e.g. OssDsign, Vanadis Diagnostics, ExScale Biospecimen Solutions. Mr. Nordström has a BSc in Business Administration and Economics from University of Uppsala, Sweden.
M.Sc. in engineering physics from the Norwegian University of Science and Technology. More than 25 years of experience in various senior positions in the Norsk Hydro Group and as CEO of BioInvent International AB. Chairman of the Boards of iCell Science AB and Gabather AB. Board member of Athera Biotechnologies AB and Arild Capital AB. Previous appointments (last five years): Board member and CEO of BioInvent International AB, Chairman of the Board of Biotec Pharmacon ASA and Board member of the industry organization Sweden Bio.
Richard Åhlberg, MD Ph.D
PhD in immunology, is chief physician at Karolinska University Hospital. He is an experienced life science board member. He has vast experience from the pharmaceutical industry with focus on immuno-oncology from his previous positions as Medical Director and Business Director Oncology at Roche AB. For five years he was the Country Manager for Aleris Healthcare Sweden.
Karin von Wachenfeldt, Ph.D
Karin has a strong scientific expertise in pharmaceutical development of large and small molecules. She obtained her Ph. D in 1993 from Dept. of Immunotechnology at Lund University. Karin has over 20 years of experience from the pharmaceutical industry (BioInvent, Ixsys Inc. PharmaciaUpjohn, Active Biotech and AstraZeneca) developing drugs for cancer and Respiratory/Inflammation. Since 2011 she is the CEO and co-founder of Truly Translational Sweden AB.
Johan Lund, Ph.D
Dr Johan Lund is currently CEO of KyNexis, a startup company he has co-founded in Sweden, and Chairman of the Board of Aqilion. Prior to this he spent 20 years in pharmaceutical industry leading Research and Early Development groups within Celgene, Pfizer and AstraZeneca in Sweden, UK and USA. Most recently he was SVP and Chief Scientific Officer for Immunoscience at Pfizer, Cambridge, MA and VP of Immunology & Inflammation Research and Early Development for Celgene, based in Cambridge, MA. Earlier in his career Dr Lund was Associate Professor at Karolinska Institutet in Stockholm and Professor and Chairman of the Anatomy and Cell Biology Department, University of Bergen Medical Faculty. He received his medical training at Karolinska Institutet where he also obtained his Ph.D, followed by post-doctoral training at UT Southwestern in Dallas.